Last reviewed · How we verify
NCT06555575
A Randomized Controlled Trial of Ubiquinone vs Ubiquinol Supplementation in Women Over Age 37 Undergoing in Vitro Fertilization.
Phase 2 trial testing Ubiquinone 200 Mg Oral Capsule in IVF in 90 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | Trio Fertility |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 23 January 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Ubiquinone 200 Mg Oral Capsule — full drug profile →
- Ubiquinol 100 MG Oral Capsule — full drug profile →
Conditions studied
- IVF — all drugs for IVF →
Sponsor
Trio Fertility — full company profile →
Who can join
Adults 37 to 43, female only, with IVF. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Fertilized oocyte percentage
Time frame: Through study completion, an average of 1 year.
The primary outcome measure will be percentage of fertilized oocytes reaching the blastocyst stage (day 5 or 6 in culture)
Sponsor's own description
The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06555575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IVF
Currently open trials in the same condition.
- NCT07364526 — Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients · recruiting
- NCT07088640 — Single Step Protocol and Multi-step Warming Protocol for Blastocyst FET · NA · recruiting
- NCT06544837 — Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation · NA · recruiting
- NCT06334003 — Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology · recruiting
- NCT06577181 — Effect of HCG on Endometrial Preparation in Frozen Embryo Transfer · active not recruiting
Other Trio Fertility trials
Trials by the same sponsor.
- NCT06117982 — The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06555575 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Trio Fertility
- Last refreshed: 7 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06555575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing